We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Anti-Cancer Treatment Targets Activated Platelets in Tumor Microenvironment

By LabMedica International staff writers
Posted on 19 Feb 2019
Print article
Image: The diagram illustrates the path of action of a new imaging and platelet targeting chemotherapy agent for the early detection and treatment of cancers (Photo courtesy of the Baker Heart and Diabetes Institute).
Image: The diagram illustrates the path of action of a new imaging and platelet targeting chemotherapy agent for the early detection and treatment of cancers (Photo courtesy of the Baker Heart and Diabetes Institute).
A novel chemotherapeutic agent transport system is based on the binding of an antibody-drug conjugate specifically directed to a surface protein on activated platelets in the tumor microenvironment.

Based on the premise that platelets in the blood are being increasingly recognized as mediators of tumor growth and metastasis, investigators at the Baker Heart and Diabetes Institute (Melbourne, Australia) hypothesized that activated platelets in the tumor microenvironment could provide a targeting epitope for tumor-directed chemotherapy.

Toward this end, the investigators developed an antibody-drug conjugate (ADC), comprised of a single-chain antibody (scFv) against the platelet integrin GPIIb/IIIa (scFvGPIIb/IIIa) protein that was linked to the potent chemotherapeutic microtubule inhibitor, monomethyl auristatin E (MMAE). The targeting scFv selectively bound to an epitope that wass hidden on the low-affinity GPIIb/IIIa of circulating platelets but became exposed on the high affinity GPIIb/IIIa, which was expressed on activated platelets.

The scFv single-chain antibody was linked chemically to the highly potent microtubule inhibitor, monomethyl auristatin E. Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerization of tubulin. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to an antibody, which directs it to the cancer cells. The chemical linker used to attach the scFv to the antibody (in this study valine-citrulline) is stable in extracellular fluid, but is cleaved by the enzyme cathepsin B once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.

To demonstrate the functionality of this novel anti-cancer ADC, with its unique activated platelet targeting, the investigators first confirmed the efficacy of scFvGPIIb/IIIa-MMAE for tumor killing in human cell lines of triple negative breast cancer, colorectal cancer, fibrosarcoma, and prostate cancer. Next, they used a triple negative breast cancer metastasis model for proof of concept in vivo studies.

Results published in the February 2019 issue of the journal Theranostics revealed that treatment of mice with scFvGPIIb/IIIa-MMAE resulted in significant regression of primary tumors and prevented metastasis without systemic side effects. Furthermore, the investigators showed that scFvGPIIb/IIIa-MMAE could be conjugated with the fluorescent dye Cyanine7 for in vivo imaging and potential diagnostic use.

"This activated platelet targeted chemotherapy approach also provides the means to deliver high concentrations of chemotherapy specifically to tumor cells whilst minimizing side effects and preventing tumor growth," said senior author Dr. Karlheinz Peter, deputy director, basic and translational science at the Baker Heart and Diabetes Institute. "This highly promising and unexpected discovery with immense importance for cancer diagnosis and therapy emerged from years of research on the function of platelets in heart disease. It is a good example of the importance of funding in basic research which often produces unexpected but highly relevant discoveries that ultimately will provide benefit for patients."

Related Links:
Baker Heart and Diabetes Institute

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.